India, March 17 -- Incyte Corporation (INCY) Monday announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating povorcitinib in adults with hidradenitis suppurativa (HS).
Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by painful nodules and abscesses.
The STOP-HS clinical trial program includes two Phase 3 studies, STOP-HS1 and STOP-HS2, evaluating the efficacy and safety of povorcitinib in adult patients with moderate to severe HS. Results from the studies showed that a significantly higher proportion of patients treated with povorcitinib achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a 50 percent or more reduction from baseline in the total abscess and...